AIIMS Patna starts paediatric trails of Bharat Biotech
All India Institute of Medical Sciences (AIIMS), Patna has started paediatric trials of Bharat Biotech’s Covaxin.
Bharat Biotech received the Drugs Controller General of India (DCGI) nod to conduct clinical trials of its COVID-19 vaccine on children in May.
VK Paul, Member (Health), Niti Aayog had informed, “Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years.”
Covaxin is India’s indigenous COVID-19 vaccine manufactured by Bharat Biotech, developed in collaboration with the Indian Council of Medical Research (ICMR).
India has given approval to three COVID-19 vaccines – Bharat Biotechs Covaxin, Serum Institute of India's Covishield and Russias Sputnik V.
Meanwhile, the Centre on Tuesday (June 1) warned that COVID-19 can have an increased impact on children if the virus changes behavior.